Opinion|Videos|January 16, 2025
Selecting the Right RCC Treatment Plan: Shared Decision-Making and Expert Advice
Panelists discuss the process of selecting a treatment plan, including how shared decision-making was approached, the key factors considered in treatment options, how patients can advocate for their preferences, and the process of recommending pembrolizumab plus lenvatinib based on clinical presentation, with a discussion of other regimens that were considered.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss the process of selecting your treatment plan. What was the process like for you in selecting a treatment plan and making shared decisions with your care team? What options were presented and how did you weigh the pros and cons?
- What were the most crucial factors you weighed in your personal decision?
- How did you advocate for your preferences during shared decision-making?
- How can patients ensure their voice is heard and their priorities addressed?
- Based on my clinical presentation and disease, what factors guided recommending pembrolizumab plus lenvatinib?
- Were other regimens considered?
- Were other regimens considered?
Advertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
3
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5